Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986165 in Healthy Chinese Subjects
NCT03956953Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration at Day 19, Time to Maximum Observed Plasma Concentration at Day 19 and 14 more. Started Apr 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03956953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956953.